 Connection
Joshua Barocas to Opioid-Related Disorders
This is a "connection" page, showing publications Joshua Barocas has written about Opioid-Related Disorders.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
9.146 |
|
|
|
-
Wang J, Doogan N, Thompson K, Bernson D, Feaster D, Villani J, Chandler R, White LF, Kline D, Barocas JA. Massachusetts Prevalence of Opioid Use Disorder Estimation Revisited: Comparing a Bayesian Approach to Standard Capture-Recapture Methods. Epidemiology. 2023 11 01; 34(6):841-849.
Score: 0.544
-
Savinkina A, Jurecka C, Gonsalves G, Barocas JA. Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study. Int J Drug Policy. 2023 Nov; 121:104175.
Score: 0.543
-
Jurecka CA, Barocas JA. Using Evidence to Inform Legislation Aimed at Curbing Fentanyl Deaths. JAMA Health Forum. 2023 01 06; 4(1):e225202.
Score: 0.517
-
Doogan NJ, Mack A, Wang J, Crane D, Jackson R, Applegate M, Villani J, Chandler R, Barocas JA. Opioid Use Disorder Among Ohio's Medicaid Population: Prevalence Estimates From 19 Counties Using a Multiplier Method. Am J Epidemiol. 2022 11 19; 191(12):2098-2108.
Score: 0.513
-
Flam-Ross JM, Lown J, Patil P, White LF, Wang J, Perry A, Bailer D, McKenzie M, Thigpen A, Newman R, Lincoln M, Mckinney T, Bernson D, Barocas JA. Factors associated with opioid-involved overdose among previously incarcerated people in the U.S.: A community engaged narrative review. Int J Drug Policy. 2022 02; 100:103534.
Score: 0.480
-
Barocas JA, Eftekhari Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, Englander H, Linas BP. Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clin Infect Dis. 2021 12 06; 73(11):e3661-e3669.
Score: 0.480
-
Barocas JA, Savinkina A, Adams J, Jawa R, Weinstein ZM, Samet JH, Linas BP. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. Lancet Public Health. 2022 01; 7(1):e56-e64.
Score: 0.479
-
Hadland SE, Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Morgan JR, Barocas JA. Opioid use disorder and overdose among youth following an initial opioid prescription. Addiction. 2021 10; 116(10):2790-2800.
Score: 0.458
-
Barocas JA, Morgan JR, Wang J, McLoone D, Wurcel A, Stein MD. Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. Clin Infect Dis. 2021 02 01; 72(3):472-478.
Score: 0.453
-
Bagley SM, Gai MJ, Earlywine JJ, Schoenberger SF, Hadland SE, Barocas JA. Incidence and Characteristics of Nonfatal Opioid Overdose Among Youths Aged 11 to 24 Years by Sex. JAMA Netw Open. 2020 12 01; 3(12):e2030201.
Score: 0.447
-
Schranz A, Barocas JA. Infective Endocarditis in Persons Who Use Drugs: Epidemiology, Current Management, and Emerging Treatments. Infect Dis Clin North Am. 2020 09; 34(3):479-493.
Score: 0.440
-
Barocas JA, Gai MJ, Amuchi B, Jawa R, Linas BP. Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug Alcohol Depend. 2020 10 01; 215:108207.
Score: 0.437
-
Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Int J Drug Policy. 2019 10; 72:160-168.
Score: 0.401
-
Barocas JA, Wang J, Marshall BDL, LaRochelle MR, Bettano A, Bernson D, Beckwith CG, Linas BP, Walley AY. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend. 2019 07 01; 200:59-63.
Score: 0.401
-
Barocas JA. Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics. Ann Intern Med. 2019 04 02; 170(7):509.
Score: 0.398
-
Barocas JA, Saitz R. Being Explicit About Decisions: Prescribe Medications for Opioid Use Disorder on the Basis of Proven Effectiveness, Not Beliefs. Ann Intern Med. 2019 01 15; 170(2):127-128.
Score: 0.391
-
Barocas JA, White LF, Wang J, Walley AY, LaRochelle MR, Bernson D, Land T, Morgan JR, Samet JH, Linas BP. Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011-2015: A Capture-Recapture Analysis. Am J Public Health. 2018 12; 108(12):1675-1681.
Score: 0.387
-
Barocas JA, Baker L, Hull SJ, Stokes S, Westergaard RP. High uptake of naloxone-based overdose prevention training among previously incarcerated syringe-exchange program participants. Drug Alcohol Depend. 2015 Sep 01; 154:283-6.
Score: 0.307
-
Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, Assoumou SA. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Netw Open. 2023 09 05; 6(9):e2329583.
Score: 0.135
-
Thompson K, Barocas JA, Delcher C, Bae J, Hammerslag L, Wang J, Chandler R, Villani J, Walsh S, Talbert J. The prevalence of opioid use disorder in Kentucky's counties: A two-year multi-sample capture-recapture analysis. Drug Alcohol Depend. 2023 01 01; 242:109710.
Score: 0.128
-
Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022 09; 117(9):2450-2461.
Score: 0.123
-
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022 10; 117(10):2635-2648.
Score: 0.123
-
King CA, Englander H, Korthuis PT, Barocas JA, McConnell KJ, Morris CD, Cook R. Designing and validating a Markov model for hospital-based addiction consult service impact on 12-month drug and non-drug related mortality. PLoS One. 2021; 16(9):e0256793.
Score: 0.118
-
Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021 08 01; 225:108764.
Score: 0.116
-
Morgan JR, Barocas JA, Murphy SM, Epstein RL, Stein MD, Schackman BR, Walley AY, Linas BP. Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. JAMA Netw Open. 2020 12 01; 3(12):e2029676.
Score: 0.112
-
Min JE, Pearce LA, Homayra F, Dale LM, Barocas JA, Irvine MA, Slaunwhite AK, McGowan G, Torban M, Nosyk B. Estimates of opioid use disorder prevalence from a regression-based multi-sample stratified capture-recapture analysis. Drug Alcohol Depend. 2020 12 01; 217:108337.
Score: 0.111
-
Morgan JR, Wang J, Barocas JA, Jaeger JL, Durham NN, Babakhanlou-Chase H, Bharel M, Walley AY, Linas BP. Opioid overdose and inpatient care for substance use disorder care in Massachusetts. J Subst Abuse Treat. 2020 05; 112:42-48.
Score: 0.106
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|